Pyridylvinylpyrazoloquinolines as PAR1 inhibitors

US8791133B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Karl Schoenafinager · Alzenau, DE
• Henning Steinhagen · Pocking, DE
• Bodo Scheiper · Frankfurt am Main, DE
• Uwe Heinelt · Wiesbaden, DE
• Volkmar Wehner · Bischofsheim a.d.Rhön, DE
• Matthias Herrmann · Hildesheim, DE
• Jacques Mauger · Tucson, US
• Pavel Safar · Tucson, US

Key dates

• Filing date: Oct 16, 2012
• Grant date: Jul 29, 2014
• Expiry date: Oct 16, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure relates to compounds of formula I:wherein the groups R1, R2, R3, R4, R5 and X are as defined in the disclosure, having antithrombotic activity, which in particular inhibits the protease-activated receptor 1 (PAR1). The disclosure further relates to methods for producing the same and to the use thereof as a pharmaceutical product.